Acute undifferentiated leukemia

Summary

Acute undifferentiated leukemia (MONDO:0020321) is a cancer and 37 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, foscarnet, and dexrazoxane. A subtype of acute leukemia of ambiguous lineage — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 37

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute undifferentiated leukemia
Mondo ID	MONDO:0020321
Orphanet	98835
NCIT	C9298
SNOMED CT	359631009
UMLS	C0280141
MedGen	79081
GARD	0016863
MedDRA	10045516
Is cancer (heuristic)	yes

Also known as: acute leukaemia not otherwise specified · acute myeloid leukemia, minimal differentiation, FAB M0 · acute undifferentiated leukemia · AUL · leukaemia stem cell · leukemia stem cell · stem cell acute leukaemia · stem cell acute leukemia · stem cell leukaemia · stem cell leukemia · undifferentiated acute leukaemia · undifferentiated acute leukemia

Disease family

This is a subtype of acute leukemia of ambiguous lineage. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › acute myeloid leukemia › acute leukemia of ambiguous lineage › acute undifferentiated leukemia

Related subtypes (2): bilineal acute myeloid leukemia, mixed phenotype acute leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 37.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	13
PHASE2	10
Not specified	7
PHASE1/PHASE2	5
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00557193	PHASE3	COMPLETED	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT03825887	PHASE3	COMPLETED	Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients
NCT03779854	PHASE2	RECRUITING	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT05589896	PHASE1/PHASE2	RECRUITING	A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT06928662	PHASE1/PHASE2	RECRUITING	Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
NCT00006251	PHASE1/PHASE2	COMPLETED	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
NCT00061945	PHASE1/PHASE2	COMPLETED	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00118352	PHASE2	COMPLETED	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00387426	PHASE2	TERMINATED	Sunitinib in Treating Patients With Idiopathic Myelofibrosis
NCT01028716	PHASE2	TERMINATED	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01273766	PHASE2	COMPLETED	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
NCT01858740	PHASE2	COMPLETED	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
NCT02135874	PHASE2	COMPLETED	Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
NCT02220985	PHASE2	COMPLETED	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
NCT02793544	PHASE2	COMPLETED	HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
NCT04044560	PHASE2	TERMINATED	Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
NCT05322850	PHASE1/PHASE2	SUSPENDED	Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
NCT03326921	PHASE1	RECRUITING	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
NCT04980404	PHASE1	ACTIVE_NOT_RECRUITING	Inqovi Maintenance Therapy in Myeloid Neoplasms
NCT05476770	PHASE1	RECRUITING	Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT07254793	PHASE1	NOT_YET_RECRUITING	Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
NCT00025415	PHASE1	COMPLETED	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00079404	PHASE1	COMPLETED	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
NCT00098826	PHASE1	COMPLETED	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
NCT00459212	PHASE1	COMPLETED	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
NCT00890747	PHASE1	COMPLETED	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
NCT00933985	PHASE1	TERMINATED	Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
NCT01231919	PHASE1	COMPLETED	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
NCT05170828	PHASE1	WITHDRAWN	Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
NCT05326516	PHASE1	COMPLETED	A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT01199562	Not specified	ACTIVE_NOT_RECRUITING	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
NCT00014235	Not specified	COMPLETED	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
NCT00112593	Not specified	COMPLETED	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
NCT00606216	Not specified	COMPLETED	Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
NCT00898079	Not specified	COMPLETED	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
NCT01053494	Not specified	COMPLETED	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
NCT01869777	Not specified	COMPLETED	Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MERCAPTOPURINE ANHYDROUS	4	6
FOSCARNET	4	4
DEXRAZOXANE	4	3
2-MERCAPTOETHANESULFONIC ACID	4	2
ALEMTUZUMAB	4	2
ASPARAGINASE	4	2
ACYCLOVIR	4	1
ALLOPURINOL	4	1
BLINATUMOMAB	4	1
CLOFARABINE	4	1
DAUNORUBICIN HYDROCHLORIDE	4	1
DEFERASIROX	4	1
GANCICLOVIR	4	1
HYDROCORTISONE	4	1
IMATINIB	4	1
LEUCOVORIN	4	1
NALBUPHINE	4	1
PEGASPARGASE	4	1
REVUMENIB	4	1
SORAFENIB TOSYLATE	4	1
SUNITINIB MALATE	4	1
TAGRAXOFUSP	4	1
VALGANCICLOVIR	4	1
LESTAURTINIB	3	1
OBATOCLAX MESYLATE	3	1
TANESPIMYCIN	3	1
GTI-2040	2	1
ISPINESIB	2	1
CHEMBL290077	0	5
CHEMBL4469622	0	1